The FDA has cleared an investigational new drug request from Evolva Holding SA, of Reinach, Switzerland, paving the way for a human trial of EV-077 to treat influenza. In preclinical testing, the candidate showed potential as prophylaxis and treatment of various viral infections, according to the company.